Details of the Drug Combinations

General Information of This Drug (ID: DM48K0X)

• Drug Name: Carfilzomib (DM48K0X)
• Synonyms: Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide

Indication

Multiple myeloma; ICD 11: 2A83; Status: Approved [1]; Plasma cell myeloma; ICD 11: 2A83.1; Status: Approved [2]; Small-cell lung cancer; ICD 11: 2C25.Y; Status: Phase 1/2 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

89 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
(-)-englerin A + Carfilzomib	DC6XR0Z	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[4]
Abexinostat + Carfilzomib	DC3QJ8L	Abexinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
ABT-199 + Carfilzomib	DC6JUCQ	ABT-199	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
ABT-263 + Carfilzomib	DCXEWGI	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Carfilzomib	DC2UMYK	ABT-263	Glioblastoma (Cell Line: JHH-136)	[5]
Afatinib + Carfilzomib	DCV15QM	Afatinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Alvespimycin hydrochloride + Carfilzomib	DCM7P27	Alvespimycin hydrochloride	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
AS602868 + Carfilzomib	DCD6UC4	AS602868	Glioblastoma (Cell Line: JHH-136)	[4]
AZD8055 + Carfilzomib	DC090AK	AZD8055	Ewing sarcoma (Cell Line: TC-71)	[4]
BGT226 + Carfilzomib	DCFALFV	BGT226	Hepatoblastoma (Cell Line: HB3)	[5]
BMS-754807 + Carfilzomib	DC5JLI3	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Buparlisib + Carfilzomib	DCHJBV2	Buparlisib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Calindol + Carfilzomib	DC8RM10	Calindol	DD2 (Cell Line: DD2)	[4]
Carfilzomib + Buparlisib	DCHI101	Buparlisib	Ewing sarcoma (Cell Line: TC-71)	[4]
Carfilzomib + JQ1	DC9BWGL	JQ1	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + JQ1	DCZ39N1	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + Artemether	DCA29IU	Artemether	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Panobinostat	DCEPXWJ	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Panobinostat	DCOOF2I	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + AZD8055	DCS7COI	AZD8055	Ewing sarcoma (Cell Line: TC-71)	[4]
Carfilzomib + Formononetin	DCKX137	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[4]
Carfilzomib + Abexinostat	DC4BEMG	Abexinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + CUDC-101	DC1RT7D	CUDC-101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + RAF265	DCT4GV7	RAF265	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Daporinad	DCKWR5V	Daporinad	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + THAPSIGARGIN	DCNDRHF	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[4]
Carfilzomib + Mitomycin	DCNV0G0	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
Carfilzomib + SNDX-275	DCUIZT2	SNDX-275	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + SNDX-275	DCHG6DF	SNDX-275	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + Ciclopirox	DC3DDCR	Ciclopirox	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Resminostat	DCZ4H70	Resminostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + Bardoxolone methyl	DC2EBWE	Bardoxolone methyl	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Artemisinin	DC2DTWZ	Artemisinin	DD2 (Cell Line: DD2)	[4]
Carfilzomib + Artemisinin	DC15SJL	Artemisinin	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + CF102	DCUITO2	CF102	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + Clomiphene citrate	DC56Y7X	Clomiphene citrate	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Chloroquine	DC09ZJ4	Chloroquine	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Naltrexone	DCSP3FK	Naltrexone	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Quinine	DCUJ5G4	Quinine	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Romidepsin	DCUDWUG	Romidepsin	Ewing sarcoma (Cell Line: TC-71)	[4]
Carfilzomib + Piperaquine	DCG3TC1	Piperaquine	DD2 (Cell Line: DD2)	[4]
Carfilzomib + Piperaquine	DCIDVLM	Piperaquine	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Pyronaridine	DC48KB8	Pyronaridine	DD2 (Cell Line: DD2)	[4]
Carfilzomib + Pyronaridine	DCZCKBS	Pyronaridine	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + Mefloquine	DCHCP60	Mefloquine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Vinpocetine	DCMN1XQ	Vinpocetine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Auranofin	DCV60XW	Auranofin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Carfilzomib + Vorinostat	DCOQ15A	Vorinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Carfilzomib + Atovaquone	DCJAU51	Atovaquone	Hepatoblastoma (Cell Line: HB3)	[4]
Carfilzomib + CB3304	DC78IZX	CB3304	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
CF102 + Carfilzomib	DCZDHCG	CF102	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
CHS-828 + Carfilzomib	DCSTHF3	CHS-828	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Crizotinib + Carfilzomib	DCUT6I6	Crizotinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Daporinad + Carfilzomib	DCEA2GQ	Daporinad	Ewing sarcoma (Cell Line: TC-71)	[4]
Eltanexor oral + Carfilzomib	DCX74SZ	Eltanexor oral	Ewing sarcoma (Cell Line: TC-71)	[4]
Evacetrapib + Carfilzomib	DCTTQD3	Evacetrapib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Everolimus + Carfilzomib	DCNNAMF	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[4]
Fenretinide + Carfilzomib	DC0YZL1	Fenretinide	Glioblastoma (Cell Line: JHH-136)	[4]
GDC-0084 + Carfilzomib	DC54JBM	GDC-0084	Ewing sarcoma (Cell Line: TC-71)	[4]
GSK-2256098 + Carfilzomib	DCJC9DM	GSK-2256098	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
GSK2126458 + Carfilzomib	DCC7ULR	GSK2126458	Glioblastoma (Cell Line: JHH-136)	[4]
Ixazomib + Carfilzomib	DCDP1F3	Ixazomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Ixazomib + Carfilzomib	DC8YF94	Ixazomib	Glioblastoma (Cell Line: JHH-136)	[4]
JQ1 + Carfilzomib	DC5FTDR	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
KN-62 + Carfilzomib	DCB84PH	KN-62	DD2 (Cell Line: DD2)	[4]
Lumefantrine + Carfilzomib	DC878IQ	Lumefantrine	DD2 (Cell Line: DD2)	[4]
LY2874455 + Carfilzomib	DCD2LNT	LY2874455	Ewing sarcoma (Cell Line: TC-71)	[4]
Mitomycin + Carfilzomib	DC2PDKP	Mitomycin	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-1775 + Carfilzomib	DC9US21	MK-1775	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + Carfilzomib	DC8RYOL	MK-2206	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
MK-2206 + Carfilzomib	DC60TP7	MK-2206	Ewing sarcoma (Cell Line: TC-71)	[4]
OSI-906 + Carfilzomib	DCO46XR	OSI-906	Ewing sarcoma (Cell Line: TC-71)	[5]
PAC1 + Carfilzomib	DCNXK68	PAC1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
PAC1 + Carfilzomib	DCMNI52	PAC1	Glioblastoma (Cell Line: JHH-136)	[4]
Panobinostat + Carfilzomib	DCYU204	Panobinostat	Ewing sarcoma (Cell Line: TC-71)	[4]
Pelitinib + Carfilzomib	DC96ANY	Pelitinib	Glioblastoma (Cell Line: JHH-136)	[4]
Plinabulin + Carfilzomib	DC5WIAH	Plinabulin	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Pyrazinamide + Carfilzomib	DC1HOAM	Pyrazinamide	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Raloxifene + Carfilzomib	DCYO0AS	Raloxifene	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
RTB101 + Carfilzomib	DCN9DEL	RTB101	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Selumetinib + Carfilzomib	DC9T5EG	Selumetinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
SGC707 + Carfilzomib	DCW7BAL	SGC707	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
TAK-733 + Carfilzomib	DC8GO43	TAK-733	Glioblastoma (Cell Line: JHH-136)	[4]
THAPSIGARGIN + Carfilzomib	DCILW5C	THAPSIGARGIN	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
THZ1 + Carfilzomib	DCB7CY2	THZ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Topetecan + Carfilzomib	DC7L5BX	Topetecan	Glioblastoma (Cell Line: JHH-136)	[4]
Trametinib + Carfilzomib	DCSJAS3	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Triptolide + Carfilzomib	DCIXBUT	Triptolide	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Vincristine + Carfilzomib	DCNDTI5	Vincristine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]

29 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Carfilzomib + Romidepsin	DC4FRYE	Romidepsin	Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma	[6]
Carfilzomib + Panobinostat	DC615HS	Panobinostat	Non-Secretory Plasma Cell Myeloma	[7]
Carfilzomib + ARRY-520	DCIEV82	ARRY-520	Plasma Cell Leukemia	[8]
Carfilzomib + Panobinostat	DCRD9AR	Panobinostat	Multiple Myeloma	[9]
Carfilzomib + Lenalidomide	DCTXXK8	Lenalidomide	T-cell Lymphomas	[10]
Carfilzomib + Tacrolimus	DCEMT1F	Tacrolimus	Hematologic Malignancies	[11]
Carfilzomib + Umbralisib	DCHS2BT	Umbralisib	Hodgkin Disease	[12]
Carfilzomib + Irinotecan	DCJJKNH	Irinotecan	Small Cell Lung Carcinoma	[13]
Carfilzomib + Belinostat	DCLIUUB	Belinostat	Non-Hodgkin Lymphoma	[14]
Carfilzomib + Ibrutinib	DCPX255	Ibrutinib	Lymphoma	[15]
Carfilzomib + Romidepsin	DCPYXK2	Romidepsin	Peripheral T Cell Lymphoma	[16]
Dexamethasone + Carfilzomib	DC4D1ZK	Dexamethasone	Multiple Myeloma	[17]
Dexamethasone + Carfilzomib	DCT9A4G	Dexamethasone	Waldenstrom's Macroglobulinemia	[18]
Dexamethasone + Carfilzomib	DCXNKIO	Dexamethasone	Multiple Myeloma	[19]
Dexamethasone + Carfilzomib	DC03O1X	Dexamethasone	Multiple Myeloma	[20]
Dexamethasone + Carfilzomib	DC3H4D0	Dexamethasone	Multiple Myeloma	[21]
Dexamethasone + Carfilzomib	DC5ITF8	Dexamethasone	Multiple Myeloma	[22]
Dexamethasone + Carfilzomib	DCE18BM	Dexamethasone	Multiple Myeloma	[23]
Dexamethasone + Carfilzomib	DCH2WO3	Dexamethasone	Multiple Myeloma	[24]
Dexamethasone + Carfilzomib	DCO0ZYT	Dexamethasone	Multiple Myeloma	[25]
Dexamethasone + Carfilzomib	DCTATFC	Dexamethasone	Relapsed Multiple Myeloma	[26]
Carfilzomib + Methylprednisolone	DCQLZ6O	Methylprednisolone	Multiple Myeloma	[27]
Carfilzomib + Pomalidomide	DCS1PR0	Pomalidomide	Recurrent Plasma Cell Myeloma	[28]
Dexamethasone + Carfilzomib	DC3KY0V	Dexamethasone	Multiple Myeloma	[29]
Dexamethasone + Carfilzomib	DC7BOG6	Dexamethasone	Multiple Myeloma	[30]
Dexamethasone + Carfilzomib	DC7ERXM	Dexamethasone	Multiple Myeloma	[27]
Dexamethasone + Carfilzomib	DCO2B1U	Dexamethasone	Metastatic Castration-resistant Prostate Cancer	[31]
Dexamethasone + Carfilzomib	DCJ5PDP	Dexamethasone	Relapsed or Refractory Multiple Myeloma	[32]
Dexamethasone + Carfilzomib	DCKXV9A	Dexamethasone	Relapsed Multiple Myeloma	[33]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7420).
• [2] Carfilzomib FDA Label
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [6] ClinicalTrials.gov (NCT01738594) Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
• [7] ClinicalTrials.gov (NCT01301807) Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
• [8] ClinicalTrials.gov (NCT01372540) Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
• [9] ClinicalTrials.gov (NCT01496118) Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
• [10] ClinicalTrials.gov (NCT02341014) Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
• [11] ClinicalTrials.gov (NCT02145403) Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
• [12] ClinicalTrials.gov (NCT02867618) Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
• [13] ClinicalTrials.gov (NCT01941316) Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
• [14] ClinicalTrials.gov (NCT02142530) Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
• [15] ClinicalTrials.gov (NCT02269085) Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
• [16] ClinicalTrials.gov (NCT03141203) Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
• [17] ClinicalTrials.gov (NCT01568866) Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
• [18] ClinicalTrials.gov (NCT00150462) Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
• [19] ClinicalTrials.gov (NCT02802163) Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
• [20] ClinicalTrials.gov (NCT02773030) A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
• [21] ClinicalTrials.gov (NCT01962792) Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
• [22] ClinicalTrials.gov (NCT01665794) Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
• [23] ClinicalTrials.gov (NCT02335983) Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
• [24] ClinicalTrials.gov (NCT01660750) A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
• [25] ClinicalTrials.gov (NCT01549431) Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
• [26] ClinicalTrials.gov (NCT00603447) Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
• [27] ClinicalTrials.gov (NCT02294357) Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
• [28] ClinicalTrials.gov (NCT04850599) Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
• [29] ClinicalTrials.gov (NCT02899052) Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
• [30] ClinicalTrials.gov (NCT01572480) Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
• [31] ClinicalTrials.gov (NCT02047253) Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
• [32] ClinicalTrials.gov (NCT05572515) A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
• [33] ClinicalTrials.gov (NCT01080391) Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma